TC BioPharm (Holdings) PLC announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000. This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment. The Company expects to implement the improved manufacture process into its current facility in the next 24 months.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 USD | +0.81% | -14.48% | -60.88% |
1st Jan change | Capi. | |
---|---|---|
-60.88% | 3.9M | |
+23.37% | 47.02B | |
+49.96% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- TCBP Stock
- News TC Biopharm (Holdings) Plc
- TC BioPharm PLC Increases Treatment Capacity with Expanded Manufacturing Process